Pleural Mesothelioma
A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal that affects other cells. When…
Primary Outcome Measures Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year. ] Inclusion Criteria Signed consent to long-term follow-up on protocol PA17-0483 Patients with advanced clear cell renal cell carcinoma, osteosarcoma or mesothelioma, with an…
A specific type of radiation could be useful for the treatment of mesothelioma. Carbon-ion beam irradiation along with the chemotherapy drug cisplatin could potentially stop the growth of pleural mesothelioma tumors. Research was conducted at a carbon ion center in Chiba, Japan and results have been published to the American Journal of Cancer Research. Carbon…
Immunotherapy before aggressive surgery shows great promise for pleural mesothelioma. The combination has shown that it can improve survival for a group of patients with pleural mesothelioma in a phase II study at Baylor College of Medicine. The treatment uses two immune checkpoint inhibitors, durvalumab and tremelimumab. The two drugs have shown that they can…
Primary Outcome Measures Progression free survival [ Time Frame: From randomisation up to 2 years of follow up ] Defined as the time from randomisation to the date of disease progression Overall survival [ Time Frame: From randomisation up to 2 years of follow up ] defined as the time from randomisation to the date of death from any cause. Secondary Outcome Measures…
The most aggressive surgery for mesothelioma could be more beneficial for patients with the disease. The more aggressive surgery is called an extrapleural pneumonectomy (EPP), which involves removing the lung. The other surgery, pleurectomy and decortication (P/D), spares the lung and only removes the lining of the lung and visible tumors. A study from Italy…
A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of Opdivo and Yervoy. The combination…
When people are diagnosed with mesothelioma, it is common for the disease to spread. This occurs in around 60 percent of people, but it does not usually spread to the brain. Researchers in Great Britain believe doctors should be focusing on cerebral metastasis in mesothelioma patients in addition to other areas of the body because…
Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is able to limit an amino…
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for solid tumors (including mesothelioma) that…
